Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$397.48 0.22 (0.06%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 103.36(B)
Last Volume: 682,467 Avg Vol: 1,619,368
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 67,740 152,280 258,193 599,211
Total Sell Value $28,555,052 $61,805,647 $99,413,137 $200,212,570
Total People Sold 8 12 15 18
Total Sell Transactions 28 41 68 132
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 3258
  Page 2 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-20 4 AS $420.79 $201,979 D/D (480) 59,827 -6%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-20 4 D $420.58 $1,418,616 D/D (3,373) 60,307     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-20 4 D $420.58 $1,731,948 D/D (4,118) 13,778     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-20 4 AS $420.79 $1,684,002 D/D (4,002) 37,024 -6%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-20 4 D $420.58 $1,182,671 D/D (2,812) 41,026     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-02-20 4 D $420.58 $1,182,671 D/D (2,812) 56,892     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-20 4 D $420.58 $1,182,671 D/D (2,812) 40,248     -
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-20 4 AS $420.79 $337,053 D/D (801) 19,710 -6%     
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-20 4 D $420.58 $473,153 D/D (1,125) 20,511     -
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-20 4 AS $420.79 $2,021,475 D/D (4,804) 63,042 -6%     
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-20 4 D $420.58 $1,418,616 D/D (3,373) 67,846     -
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-16 4 D $424.01 $1,483,187 D/D (3,498) 70,866     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-16 4 D $424.01 $3,968,310 D/D (9,359) 152,912     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-16 4 D $424.01 $1,907,621 D/D (4,499) 63,680     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-16 4 D $424.01 $1,590,038 D/D (3,750) 43,838     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-02-16 4 D $424.01 $1,590,038 D/D (3,750) 59,704     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-16 4 D $424.01 $1,590,038 D/D (3,750) 43,060     -
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-16 4 D $424.01 $636,439 D/D (1,501) 21,636     -
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-16 4 D $424.01 $1,907,621 D/D (4,499) 71,219     -
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-15 4 AS $419.16 $1,951,190 D/D (4,655) 17,896 -7%     
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-14 4 AS $419.04 $1,825,338 D/D (4,356) 22,551 -5%     
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-13 4 AS $419.13 $308,899 D/D (737) 26,907 -4%     
   Leiden Jeffrey M Executive Chairman   •       •      –    2024-02-12 4 AS $419.22 $1,114,205 D/D (2,656) 27,644 -5%     
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-12 4 AS $420.24 $1,354,013 D/D (3,222) 74,364 -5%     
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-12 4 AS $420.24 $1,804,931 D/D (4,295) 75,718 -5%     
  3258 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us